Sirtuins (SIRT1-7) are NAD
+-dependent protein deacetylases/ADP ribosyltransferases with important roles in chromatin silencing, cell cycle regulation, cellular differentiation, cellular stress response, metabolism and aging. Sirtuins are components of the epigenetic machinery, which is disturbed in Alzheimer’s disease (AD), contributing to AD
[...] Read more.
Sirtuins (SIRT1-7) are NAD
+-dependent protein deacetylases/ADP ribosyltransferases with important roles in chromatin silencing, cell cycle regulation, cellular differentiation, cellular stress response, metabolism and aging. Sirtuins are components of the epigenetic machinery, which is disturbed in Alzheimer’s disease (AD), contributing to AD pathogenesis. There is an association between the
SIRT2-C/T genotype (rs10410544) (50.92%) and AD susceptibility in the
APOEε4-negative population (
SIRT2-C/C, 34.72%;
SIRT2-T/T 14.36%). The integration of
SIRT2 and
APOE variants in bigenic clusters yields 18 haplotypes. The 5 most frequent bigenic genotypes in AD are
33CT (27.81%),
33CC (21.36%),
34CT (15.29%),
34CC (9.76%) and
33TT (7.18%). There is an accumulation of
APOE-3/4 and
APOE-4/4 carriers in
SIRT2-T/T >
SIRT2-C/T >
SIRT2-C/C carriers, and also of
SIRT2-T/T and
SIRT2-C/T carriers in patients who harbor the
APOE-4/4 genotype.
SIRT2 variants influence biochemical, hematological, metabolic and cardiovascular phenotypes, and modestly affect the pharmacoepigenetic outcome in AD.
SIRT2-C/T carriers are the best responders,
SIRT2-T/T carriers show an intermediate pattern, and
SIRT2-C/C carriers are the worst responders to a multifactorial treatment. In
APOE-SIRT2 bigenic clusters,
33CC carriers respond better than
33TT and
34CT carriers, whereas
24CC and
44CC carriers behave as the worst responders. CYP2D6 extensive metabolizers (EM) are the best responders, poor metabolizers (PM) are the worst responders, and ultra-rapid metabolizers (UM) tend to be better responders that intermediate metabolizers (IM). In association with
CYP2D6 genophenotypes,
SIRT2-C/T-EMs are the best responders. Some Sirtuin modulators might be potential candidates for AD treatment.
Full article